Financing ·
Cellectar Biosciences reported a net loss of $6.9 million ($0.57 per share) for the quarter ended June 30, 2026…
CLRBCellectar Biosciences, Inc.
Cellectar Biosciences reported a net loss of $6.9 million ($0.57 per share) for the quarter ended June 30, 2026, compared to a $5.4 million loss in the prior year period. Cash and cash equivalents increased to $34.0 million from $13.2 million at year-end 2025, reflecting approximately $31.7 million in net proceeds from a May 2026 registered direct offering of common stock and warrants totaling up to $140 million. Research and development expenses rose to $4.6 million as the company initiated site activation for its confirmatory Phase 3 trial of iopofosine I-131 in Waldenström macroglobulinemia, with first patient dosing expected in early 2027 and a New Drug Application planned for mid-2027 under FDA Accelerated Approval. The company also began enrollment in the Phase 1b trial of CLR 125 for triple-negative breast cancer. Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on developing proprietary phospholipid drug conjugate therapies for cancer.